Bioinformatics visualisation specialist Qlucore has released the beta version of its Qlucore Omics Explorer 3.3 software, including a completely new Next Generation Sequencing (NGS) Module and range of new functionalities for the base version. The NGS Module will enable additional functionality related to data generated with NGS technologies, making it possible to interactively and dynamically visualise, analyse and explore NGS data.
Qlucore Omics Explorer is a next-generation bioinformatics software program for broad usage known for its friendly user interface and advanced visualisation capabilities that enables biologists and researchers who are not data analysis experts to explore NGS and data, find new answers and generate new hypotheses.
Examples include RNA-seq studies, is one of the most used techniques in modern genetics and cancer research, with the NGS Module enabling a comprehensive and synchronised view of both expression levels and genomic locations. A unique flexibility is handed to the user, who can perform a statistical test in the expression space by simply moving a cut-off slider, observing the result in the Genome browser, one of the main components in the NGS Module which, in combination with the dynamic filters, ensures that the user always visualises the most interesting regions of the genome, minimising the need for zoom and scroll.
For further information on Qlucore and its new software visit www.qlucore.com
Latest from Tom Mulligan
- Medisur and Peripal to distribute Mologic’s PERiPLEX renal disease POC diagnostic in Europe
- Glythera appoints Professor Kerry Chester to SAB
- Concept Life Sciences appoints site director and biotransformation and metabolite identification expert at Alderley Park site
- Cobra Biologics receives Queen’s Award for Enterprise in International Trade
- Isogenica licenses CIS Display Technology to Fusion Pharmaceuticals
- PATH and Mologic advance new malaria diagnostic test
- Zelluna Immunotherapy appoints Arjan Roozen as CTO
- PhoreMost and Plexxikon collaborate to identify novel drug targets
- Horizon Discovery and The Pirbright Institute partner to improve vaccine yields
- Respiratory diseases specialist Enterprise Therapeutics raises £29 million in Series B funding